Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Inovio Pharmaceuticals stock price, quote, forecast and news

INO
US45773H2013
A115GK

Price

5.86
Today +/-
+0.31
Today %
+6.16 %
P

Inovio Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Inovio Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Inovio Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Inovio Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Inovio Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Inovio Pharmaceuticals Stock Price History

DateInovio Pharmaceuticals Price
9/27/20245.86 undefined
9/26/20245.51 undefined
9/25/20245.52 undefined
9/24/20245.94 undefined
9/23/20245.88 undefined
9/20/20246.48 undefined
9/19/20246.69 undefined
9/18/20246.77 undefined
9/17/20246.78 undefined
9/16/20246.82 undefined
9/13/20246.81 undefined
9/12/20246.63 undefined
9/11/20246.55 undefined
9/10/20246.43 undefined
9/9/20246.41 undefined
9/6/20246.28 undefined
9/5/20246.50 undefined
9/4/20246.58 undefined
9/3/20246.43 undefined
8/30/20247.22 undefined

Inovio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Inovio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Inovio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Inovio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Inovio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Inovio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Inovio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Inovio Pharmaceuticals’s growth potential.

Inovio Pharmaceuticals Revenue, EBIT and net profit per share

DateInovio Pharmaceuticals RevenueInovio Pharmaceuticals EBITInovio Pharmaceuticals Net Income
2029e221.13 M undefined0 undefined35.92 M undefined
2028e324.4 M undefined129.66 M undefined104.55 M undefined
2027e177.02 M undefined13.76 M undefined24.12 M undefined
2026e16.75 M undefined-65.55 M undefined-69.35 M undefined
2025e202,000 undefined-111.79 M undefined-96.53 M undefined
2024e329,431.68 undefined-122.18 M undefined-121.34 M undefined
2023832,000 undefined-133.43 M undefined-135.12 M undefined
202210.26 M undefined-267.57 M undefined-279.82 M undefined
20211.78 M undefined-301.22 M undefined-303.66 M undefined
20207.41 M undefined-124.08 M undefined-166.41 M undefined
20194.11 M undefined-111.11 M undefined-119.36 M undefined
201830.48 M undefined-94.09 M undefined-96.97 M undefined
201742.22 M undefined-84.64 M undefined-88.21 M undefined
201635.37 M undefined-77.24 M undefined-73.74 M undefined
201540.57 M undefined-35.28 M undefined-29.19 M undefined
201410.46 M undefined-39.5 M undefined-36.12 M undefined
201313.47 M undefined-20.87 M undefined-66.03 M undefined
20124.12 M undefined-24.65 M undefined-19.67 M undefined
20119.8 M undefined-22.23 M undefined-15.25 M undefined
20106.15 M undefined-19.22 M undefined-17.61 M undefined
20099.12 M undefined-13.96 M undefined-24.41 M undefined
20082.1 M undefined-13.66 M undefined-12.97 M undefined
20074.81 M undefined-15.9 M undefined-11.23 M undefined
20063.47 M undefined-13.35 M undefined-14.35 M undefined
20055.47 M undefined-12.18 M undefined-26.36 M undefined
20041.17 M undefined-11.51 M undefined-11.71 M undefined

Inovio Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
2338540001534296941310403542304711000016177324221
-50.00-166.67-37.50-20.00----400.00-40.0033.33-50.00350.00-33.3350.00-55.56225.00-23.08300.00-12.5020.00-28.57-86.6775.00-85.71900.00----1,006.2583.05-31.79
50.0033.3333.3375.0060.00------------------------------
11163000000000000000000000000000000
-1-3-8-6-11-5-5-5-6-11-12-13-15-13-13-19-22-24-20-39-35-77-84-94-111-124-301-267-133-122-111-65131290
-50.00-100.00-266.67-75.00-220.00-125.00----1,100.00-240.00-433.33-375.00-650.00-144.44-316.67-244.44-600.00-153.85-390.00-87.50-220.00-200.00-313.33-2,775.00-1,771.43-30,100.00-2,670.00----406.257.3439.81-
-2-3-7-7-10-8-6-5-22-11-26-14-11-12-24-17-15-19-66-36-29-73-88-96-119-166-303-279-135-121-96-692410435
-50.00133.33-42.86-20.00-25.00-16.67340.00-50.00136.36-46.15-21.439.09100.00-29.17-11.7626.67247.37-45.45-19.44151.7220.559.0923.9639.5082.53-7.92-51.61-10.37-20.66-28.13-134.78333.33-66.35
0.060.070.090.110.120.140.180.210.280.370.40.660.860.921.562.152.632.843.844.935.686.16.827.718.2312.9317.419.8822.17000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Inovio Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Inovio Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
1.846.526.199.746.531.810.8813.4617.8917.1723.0227.2514.1240.6921.8530.2113.6852.6393.62162.99104.77127.4381.2389.53411.64401.32253145.29
0.740.50.781.120.90.160.080.180.420.280.331.140.670.260.030.470.833.32.87.315.8263.320.718.565.471.70
00000000000000.060.070.040.04000.030.750.490.741.330.52.5710.042.41
39339565661275700000000000000000000000
00.010.010.140.061.711.750.120.130.871.120.610.483.560.931.191.422.762.521.533.264.452.532.6440.4639.150.515.41
2.987.437.6311.618.253.682.713.7518.4418.3224.4729.0115.2644.5722.8831.9115.9758.6898.95171.85124.6138.3687.8194.2471.17448.45315.24153.11
0.661.041.181.010.90.570.30.180.160.380.390.40.350.340.280.30.362.894.587.319.0318.3215.9526.5624.0929.0217.9614.45
0000000000009.1712.3311.369.0710.79.6712.3419.9919.8311.399.416.324.93.912.012.78
0000000000000000000000000000
00002.312.352.362.252.195.996.516.1910.1312.9711.189.317.495.724.783.917.636.014.763.693.152.632.130
0.490.760.971.35000004.294.293.93.910.1110.1110.1110.1110.1110.1110.1110.5110.5110.5110.5110.5110.5110.510
0.030.020.030.030.030.030.070.050.1700.280.280.170.310.260.410.51.221.030.682.112.642.672.6725.961.430.680.61
1.181.822.182.43.242.952.722.482.5110.6611.4810.7723.7236.0633.1929.229.1729.632.8441.9949.1148.8843.349.7568.647.533.2917.84
4.169.249.8114.0111.496.635.4216.2320.9528.9835.9539.7838.9980.6356.0761.1145.1488.29131.79213.84173.71187.24131.11143.95539.77495.94348.53170.95
                                                       
6.8821.5628.3630.490.030.090.050.020.020.030.040.040.040.10.110.140.140.050.060.070.070.090.10.10.190.220.250.02
00000.050.050.060.090.10.140.150.170.170.240.240.260.260.350.440.530.560.670.710.741.371.611.711.74
-5.8-13.4-20-29.6-41-47.36-53.33-76.2-87.91-114.27-128.62-139.85-152.81-177.22-194.84-210.09-229.76-295.79-331.91-361.1-434.84-523.36-620.43-739.79-906.2-1,209.86-1,487.85-1,622.97
2.31-0.02-0.110.9-0.11.11-0.1400-0.03-0.050.110.010.1100.040.07-0.08-0.252.711.33-0.12-0.530.47-0.26-0.28-0.7-0.66
0000000000000000000000000000
3.48.158.2611.839.894.963.7215.0515.5523.4718.1531.0419.1160.5646.547.3134.3552.46111.23175.69123.28142.3986.943.44461.14399.67222.36117.35
0.640.971.381.781.390.751.030.792.161.872.011.810.383.892.381.161.045.973.439.0714.1416.2114.657.651.4724.7665.084.65
00000000.042.21.060.680.571.390.32.894.243.741.454.996.7612.916.6115.1417.4432.6636.3629.2221.04
0000.270.050.820.610.331.050.794.170.970.833.051.175.643.621.555.6115.6416.782.595.526.97.584.622.560.11
00000000000012.1112.1200000000000000
0.020.020.050.050.070.030.020000000000000000000016.77
0.660.991.422.111.511.61.661.165.43.726.863.3514.7119.356.4411.048.3828.9714.0231.4743.8235.4135.331.9941.7165.7496.8742.57
0.080.080.120.070.050.020000.01000000000000077.0218.6614.9616.620
0000000001.081.010.950.8900.050.080.160.20.50.180.180.030.030.030.030.030.030
0.030.020.010.010.040.050.040.0200.714.584.444.280.092.482.121.746.225.726.276.339.328.7629.518.2415.5412.6611.03
0.10.10.130.080.080.070.040.0201.795.595.395.170.092.532.21.96.426.226.446.519.358.78106.5636.9330.5329.311.03
0.761.11.552.181.61.671.691.185.45.5112.458.7419.8819.448.9713.2410.2835.3920.2537.9150.3344.7544.08138.5578.6396.27126.1753.6
4.169.249.8114.0111.496.635.4216.2320.9528.9830.639.7838.9980.0155.4760.5644.6487.84131.48213.59173.61187.14131.02141.98539.77495.94348.53170.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Inovio Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Inovio Pharmaceuticals's financial health and stability.

Assets

Inovio Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Inovio Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Inovio Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Inovio Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19951996nullnull1997199819992000null20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-3-1-3-7-6-10-4-8-5-5-6-11-15-12-11-12-24-17-15-19-66-36-29-73-88-96-120-167-303-279-135
00000000000000011122121133543342
00000000000000000000000000000000
0000000000003-1200-33-1-11111005-3-715019-10
0000001-4000303102151-3-249891935233272606229
00000000000000000000000000024111
00000000000000000000000000000000
-1-2-1-2-6-6-8-8-8-5-5-2-6-12-7-11-11-14-11-19-22-15-29-12-62-63-73-97-177-215-216-124
00000000000000-10000000-1-2-3-10-20-1-100
0000000-3-32000-3-16-22111-105-9-35-5416-2742-9-58-17510987
0000000-2-22000-2-14-23111-105-9-34-5220-1744-8-57-17411087
00000000000000000000000000000000
0000000000000000120-1200000000970000
22221261355141511158160282285527284795318462211814
222212613551415111414161228-928552728479531105465211814
00000000000000500000000000002000
00000000000000000000000000000000
1010403-6-6-101240-81316-10-2-1128617-3840-1228-179-24-32
-1.73-3.6500-7.65-7.02-9.58-8.960-5.88-5.55-3.09-7.24-13.05-8.41-12.16-11.7-14.24-12.25-19.92-22.55-15.56-31.2-15.22-66.5-73.5-75.64-98.84-179.5-216.94-217.19-124.69
00000000000000000000000000000000

Inovio Pharmaceuticals stock margins

The Inovio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Inovio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Inovio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Inovio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Inovio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Inovio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Inovio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Inovio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Inovio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Inovio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Inovio Pharmaceuticals Margin History

Inovio Pharmaceuticals Gross marginInovio Pharmaceuticals Profit marginInovio Pharmaceuticals EBIT marginInovio Pharmaceuticals Profit margin
2029e0 %0 %16.24 %
2028e0 %39.97 %32.23 %
2027e0 %7.77 %13.63 %
2026e0 %-391.42 %-414.13 %
2025e0 %-55,343.59 %-47,785.87 %
2024e0 %-37,088.89 %-36,831.81 %
20230 %-16,036.9 %-16,240.02 %
20220 %-2,607.43 %-2,726.74 %
20210 %-16,970.03 %-17,107.55 %
20200 %-1,674.3 %-2,245.46 %
20190 %-2,702.07 %-2,902.7 %
20180 %-308.68 %-318.12 %
20170 %-200.48 %-208.92 %
20160 %-218.38 %-208.49 %
20150 %-86.97 %-71.94 %
20140 %-377.7 %-345.43 %
20130 %-154.98 %-490.29 %
20120 %-598.32 %-477.52 %
20110 %-226.91 %-155.72 %
20100 %-312.77 %-286.64 %
20090 %-153.05 %-267.66 %
20080 %-651.36 %-618.31 %
20070 %-330.75 %-233.58 %
20060 %-384.86 %-413.78 %
20050 %-222.7 %-482.22 %
20040 %-986.38 %-1,003 %

Inovio Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Inovio Pharmaceuticals earnings per share therefore indicates how much revenue Inovio Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inovio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inovio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inovio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inovio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Inovio Pharmaceuticals Revenue, EBIT and net profit per share

DateInovio Pharmaceuticals Sales per ShareInovio Pharmaceuticals EBIT per shareInovio Pharmaceuticals Earnings per Share
2029e8.52 undefined0 undefined1.38 undefined
2028e12.5 undefined0 undefined4.03 undefined
2027e6.82 undefined0 undefined0.93 undefined
2026e0.65 undefined0 undefined-2.67 undefined
2025e0.01 undefined0 undefined-3.72 undefined
2024e0.01 undefined0 undefined-4.67 undefined
20230.04 undefined-6.02 undefined-6.09 undefined
20220.52 undefined-13.46 undefined-14.07 undefined
20210.1 undefined-17.31 undefined-17.45 undefined
20200.57 undefined-9.6 undefined-12.87 undefined
20190.5 undefined-13.51 undefined-14.51 undefined
20183.95 undefined-12.2 undefined-12.58 undefined
20176.2 undefined-12.42 undefined-12.94 undefined
20165.8 undefined-12.66 undefined-12.09 undefined
20157.14 undefined-6.21 undefined-5.14 undefined
20142.12 undefined-8.02 undefined-7.33 undefined
20133.51 undefined-5.44 undefined-17.19 undefined
20121.45 undefined-8.67 undefined-6.92 undefined
20113.72 undefined-8.45 undefined-5.8 undefined
20102.86 undefined-8.94 undefined-8.19 undefined
20095.86 undefined-8.97 undefined-15.69 undefined
20082.29 undefined-14.93 undefined-14.17 undefined
20075.56 undefined-18.4 undefined-13 undefined
20065.29 undefined-20.35 undefined-21.88 undefined
200513.81 undefined-30.74 undefined-66.57 undefined
20043.18 undefined-31.37 undefined-31.89 undefined

Inovio Pharmaceuticals business model

Inovio Pharmaceuticals Inc. is a US biotechnology and pharmaceutical company specializing in the development of DNA vaccines and immunotherapies. It was founded in 1979 by Dr. Joseph Kim and is headquartered in Plymouth Meeting, Pennsylvania. Inovio began working on DNA-based vaccines in the late 1990s and developed the Electroporation technology, which facilitates the introduction of DNA molecules into cells. The company has expanded its capabilities over the years and is able to generate immune responses against a variety of viruses and bacteria. They have also made advancements in using their technology to combat cancer. Inovio's business model is based on licensing technologies and collaborating with partners such as pharmaceutical companies, government agencies, and academic institutions. They also offer services for the development and production of DNA-based vaccines for academic and industrial customers. Inovio is divided into different divisions, including DNA vaccines for infectious diseases and oncology, platform technology, and cancer immunotherapy. They offer a wide range of DNA vaccines for infectious diseases such as HPV, HIV, hepatitis B and C, as well as Lassa fever and Ebola. Inovio has also made significant progress in the development of DNA-based immunotherapies for cancer, using Electroporation technology to train and activate T-cells against cancer cells. In terms of products, Inovio has various products in different stages of clinical development, but they have not yet received FDA approval for any of their products. However, they have successfully conducted clinical trials for vaccines such as HPV, which has shown 90% efficacy against the virus. In conclusion, Inovio is a specialized company in the development of DNA-based vaccines and immunotherapy for cancer. Their Electroporation technology has led to significant breakthroughs, and they continue to pursue partnerships and further development. With their focus on research and development and advancing their technologies, it seems that Inovio is on a path of continued success. Inovio Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Inovio Pharmaceuticals SWOT Analysis

Strengths

Inovio Pharmaceuticals Inc has several key strengths:

  • Cutting-edge Technology: Inovio is known for its innovative DNA-based immunotherapies, giving them a competitive advantage in the biopharmaceutical industry.
  • Strong Intellectual Property: The company possesses a robust patent portfolio, helping safeguard its unique technologies and providing potential licensing opportunities.
  • Experienced Management Team: Inovio is led by a team with extensive industry experience and a proven track record in drug development and commercialization.
  • Collaborative Partnerships: The company has established strategic alliances with reputable organizations, enhancing its research capabilities and potential market reach.

Weaknesses

However, Inovio Pharmaceuticals Inc also faces some weaknesses:

  • Limited Product Portfolio: Inovio's product pipeline relies heavily on a few key candidates, posing risks if any of them fail to gain regulatory approval or meet commercial expectations.
  • Financial Dependence: As a biotech company, Inovio is highly reliant on external funding sources, making it vulnerable to market uncertainties and investor sentiment.
  • Regulatory Challenges: Drug development is subject to stringent regulatory processes, and Inovio may face delays or obstacles in gaining necessary approvals for its candidates.

Opportunities

There are several potential opportunities for Inovio Pharmaceuticals Inc:

  • Emerging Markets: Expansion into developing countries with growing healthcare needs presents opportunities for Inovio to tap into new patient populations.
  • High Demand for Vaccines: The global demand for vaccines is increasing, and Inovio's focus on immunotherapies positions them well to address this demand and potentially gain market share.
  • Partnership Collaborations: Inovio can explore further partnerships and collaborations with other pharmaceutical companies or research institutions to leverage their expertise and broaden their product portfolio.

Threats

Inovio Pharmaceuticals Inc should be aware of the following threats:

  • Intense Competition: The biopharmaceutical industry is highly competitive, with numerous players vying for market share and breakthrough therapies. Inovio faces competition from both established companies and emerging startups.
  • Clinical Trial Risks: The success of Inovio's product candidates depends on the outcomes of rigorous clinical trials, which can be costly, time-consuming, and subject to uncertainty.
  • Regulatory Changes: Changes in regulations, healthcare policies, or intellectual property laws can significantly impact Inovio's operations, market access, and profitability.

Inovio Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Inovio Pharmaceuticals Revenue by Segment

Segmente20232021202020192018
Revenue under collaborative research and development arrangements-902,260 USD5.17 M USD3.64 M USD29.86 M USD
Grants and miscellaneous revenue----6.32 M USD
Grants and miscellaneous revenue from affiliated entity---1,800 USD3.35 M USD
Revenue under collaborative research and development arrangements from affiliated entities-245,310 USD1.45 M USD--
Other revenue-627,188 USD786,904 USD--
Revenue under collaborative research and development arrangements with affiliated entity----449,524 USD
Miscellaneous revenue, including from affiliated entities---237,536 USD-
Revenue under collaborative research and development arrangements with affiliated entities---235,649 USD-
Other revenue from affiliated entities-----
Revenue under collaborative research and development arrangements from affiliated entities-----

Inovio Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Inovio Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Inovio Pharmaceuticals shares outstanding

The number of shares was Inovio Pharmaceuticals in 2023 — This indicates how many shares 22.174 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inovio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inovio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inovio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inovio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Inovio Pharmaceuticals Stock splits

In Inovio Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Inovio Pharmaceuticals.

Inovio Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.11 -1.19  (-6.95 %)2024 Q2
3/31/2024-1.01 -1.31  (-29.27 %)2024 Q1
12/31/2023-1.28 -1.12  (12.51 %)2023 Q4
9/30/2023-1.54 -1.56  (-1.62 %)2023 Q3
6/30/2023-1.76 -1.56  (11.23 %)2023 Q2
3/31/2023-1.76 -1.92  (-9.25 %)2023 Q1
12/31/2022-2.04 -2.52  (-23.76 %)2022 Q4
9/30/2022-0.3 -0.15  (49.78 %)2022 Q3
6/30/2022-0.31 -0.46  (-46.12 %)2022 Q2
3/31/2022-0.35 -0.36  (-3.81 %)2022 Q1
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Inovio Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

62/ 100

🌱 Environment

63

👫 Social

87

🏛️ Governance

34

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees50
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Inovio Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
6.34504 % The Vanguard Group, Inc.1,647,172-25,73112/31/2023
2.34251 % Renaissance Technologies LLC608,115200,65712/31/2023
1.26238 % BlackRock Institutional Trust Company, N.A.327,714-153,04012/31/2023
1.21871 % GSA Capital Partners LLP316,377291,63112/31/2023
0.92175 % Geode Capital Management, L.L.C.239,28710,03512/31/2023
0.86709 % D. E. Shaw & Co., L.P.225,097-234,80612/31/2023
0.75308 % Kim (Jong Joseph Ph.D.)195,500011/16/2023
0.36915 % Jacobs Levy Equity Management, Inc.95,831012/31/2023
0.30949 % Weiner (David B)80,34303/25/2024
0.28538 % Acadian Asset Management LLC74,08435,73412/31/2023
1
2
3
4
5
...
10

Inovio Pharmaceuticals Executives and Management Board

Dr. Jacqueline Shea57
Inovio Pharmaceuticals President, Chief Executive Officer, Director (since 2019)
Compensation 3.52 M
Mr. Peter Kies59
Inovio Pharmaceuticals Chief Financial Officer
Compensation 1.62 M
Dr. Laurent Humeau56
Inovio Pharmaceuticals Chief Scientific Officer
Compensation 1.57 M
Dr. David Weiner67
Inovio Pharmaceuticals Director
Compensation 452,970
Mr. Simon Benito78
Inovio Pharmaceuticals Independent Chairman of the Board
Compensation 186,344
1
2
3

Inovio Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
QIAGEN Stock
QIAGEN
SupplierCustomer0,270,540,660,890,620,02
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,150,45-0,38-0,71-0,67-0,35
OncoSec Medical Stock
OncoSec Medical
SupplierCustomer-0,330,710,880,620,880,52
Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals
SupplierCustomer-0,33-0,070,38-0,23-0,46-0,23
1

Most common questions regarding Inovio Pharmaceuticals

What values and corporate philosophy does Inovio Pharmaceuticals represent?

Inovio Pharmaceuticals Inc represents a core set of values and a corporate philosophy centered around innovation and advancement in the biotechnology sector. As a leader in DNA medicines, Inovio is committed to developing cutting-edge technologies and therapies to address unmet medical needs. The company's focus on research and development, alongside strategic partnerships, enables it to deliver groundbreaking solutions for infectious diseases, oncology, and other critical areas of healthcare. Inovio's dedication to scientific excellence, patient-centric approaches, and a forward-thinking vision drives its mission to transform patient outcomes and contribute to the future of global health.

In which countries and regions is Inovio Pharmaceuticals primarily present?

Inovio Pharmaceuticals Inc is primarily present in the United States, with headquarters located in Plymouth Meeting, Pennsylvania. The company focuses on developing DNA-based immunotherapies and vaccines to prevent and treat a wide range of infectious diseases and cancers. With a mission to revolutionize health by transforming the way diseases are prevented and treated, Inovio Pharmaceuticals Inc is committed to global healthcare innovation.

What significant milestones has the company Inovio Pharmaceuticals achieved?

Inovio Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and commercialized its proprietary DNA-based immunotherapies for multiple diseases, including cancer and infectious diseases. Inovio's breakthroughs also include the first-ever demonstration of proof-of-concept for a DNA vaccine against the Zika virus. In addition, the company has advanced numerous candidates into clinical trials, demonstrating its commitment to advancing innovative treatments. They have established partnerships and collaborations with leading organizations and received grants from prestigious institutions for their groundbreaking research. These achievements highlight Inovio Pharmaceuticals Inc's dedication to revolutionizing healthcare through cutting-edge technologies and expanding their portfolio of novel therapies.

What is the history and background of the company Inovio Pharmaceuticals?

Inovio Pharmaceuticals Inc, an innovative biotechnology company, has a rich history and background. Founded in 1979, Inovio has been at the forefront of advancing DNA medicines to treat and prevent infectious diseases, cancer, and immune-mediated conditions. The company has made significant strides in developing and commercializing novel immunotherapies, utilizing its proprietary DNA-based platform. Inovio's cutting-edge technology has paved the way for transformative medical advancements, garnering partnerships with leading organizations and attracting global recognition. With a strong commitment to research, development, and collaboration, Inovio Pharmaceuticals Inc continues to drive innovation and make a positive impact on global healthcare.

Who are the main competitors of Inovio Pharmaceuticals in the market?

The main competitors of Inovio Pharmaceuticals Inc in the market are Moderna Inc, Pfizer Inc, BioNTech SE, and Johnson & Johnson. These companies operate in the pharmaceutical and biotechnology industries, specializing in the research, development, and commercialization of innovative therapies and vaccines. Inovio Pharmaceuticals Inc faces competition in areas such as DNA-based immunotherapeutics, cancer treatments, infectious diseases, and infectious disease prevention. While Inovio Pharmaceuticals Inc has its unique approach and expertise in the field, it operates within a dynamic industry where competition is essential for driving innovation and advancing patient care.

In which industries is Inovio Pharmaceuticals primarily active?

Inovio Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Inovio Pharmaceuticals?

The business model of Inovio Pharmaceuticals Inc focuses on the development and commercialization of DNA-based immunotherapies and vaccines to prevent and treat infectious diseases and cancers. Inovio's innovative platform called Synthetic Nucleic Acid represents a promising approach to stimulate targeted immune responses in patients. By combining immunotherapy with its proprietary electroporation delivery technology, the company aims to revolutionize the way diseases are prevented and treated. Inovio Pharmaceuticals Inc aims to partner with other organizations and actively engage in research collaborations to accelerate its drug development programs and expand its product portfolio.

What is the P/E ratio of Inovio Pharmaceuticals 2024?

The Inovio Pharmaceuticals P/E ratio is -1.07.

What is the P/S ratio of Inovio Pharmaceuticals 2024?

The Inovio Pharmaceuticals P/S ratio is 394.44.

What is the AlleAktien quality score of Inovio Pharmaceuticals?

The AlleAktien quality score for Inovio Pharmaceuticals is 3/10.

What is the revenue of Inovio Pharmaceuticals 2024?

The expected Inovio Pharmaceuticals revenue is 329,431.68 USD.

How high is the profit of Inovio Pharmaceuticals 2024?

The expected Inovio Pharmaceuticals profit is -121.34 M USD.

What is the business model of Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a US-American company specializing in the development of drugs and vaccines against infectious diseases. Its business model is based on researching and developing new technologies for producing innovative vaccines specifically targeted at fighting viral and bacterial infections. The company works in various areas, including the development of therapeutics and vaccines against cancer and infectious diseases such as HIV, HPV, and Hepatitis B. Inovio's main product is the DNA-based IMP321 vaccine for breast cancer, which is used as an adjuvant to improve the effectiveness of chemotherapy and radiotherapy. The company has also successfully developed a DNA vaccine against the Zika virus and is currently conducting clinical trials to evaluate its effectiveness and safety. It utilizes its patented technologies to produce DNA-based drugs and vaccines and has a wide portfolio of DNA-based technologies, including the SynCon vaccine, electroporation technologies, and Cellectra immunotherapy platforms. The company also collaborates with other pharmaceutical companies, academic institutions, and government agencies in vaccine and drug research and development. It has partnerships with Roche and AstraZeneca, for example, to utilize its technologies in tracking the development of vaccines against cancer and viral infections. Additionally, it has established collaborations with the Bill and Melinda Gates Foundation and the National Institutes of Health (NIH) for the development of Zika vaccines. Inovio Pharmaceuticals Inc has positioned itself as a leading company in the research and development of DNA-based products. With its innovative technologies and focus on fighting infectious diseases, the company has the potential to have a significant impact on the healthcare industry.

What is the Inovio Pharmaceuticals dividend?

Inovio Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Inovio Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Inovio Pharmaceuticals or the company does not pay out a dividend.

What is the Inovio Pharmaceuticals ISIN?

The ISIN of Inovio Pharmaceuticals is US45773H2013.

What is the Inovio Pharmaceuticals WKN?

The WKN of Inovio Pharmaceuticals is A115GK.

What is the Inovio Pharmaceuticals ticker?

The ticker of Inovio Pharmaceuticals is INO.

How much dividend does Inovio Pharmaceuticals pay?

Over the past 12 months, Inovio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inovio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Inovio Pharmaceuticals?

The current dividend yield of Inovio Pharmaceuticals is .

When does Inovio Pharmaceuticals pay dividends?

Inovio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inovio Pharmaceuticals?

Inovio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Inovio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inovio Pharmaceuticals located?

Inovio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inovio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inovio Pharmaceuticals from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Inovio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Inovio Pharmaceuticals in the year 2023?

In the year 2023, Inovio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Inovio Pharmaceuticals pay out the dividend?

The dividends of Inovio Pharmaceuticals are distributed in USD.

All fundamentals about Inovio Pharmaceuticals

Our stock analysis for Inovio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inovio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.